Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294627 | 0.82 | NPC1 (0.53) | SLC27A1NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL12199716 | 0.77 | RAB9A (0.75) | NPC1RAB9ASMN1; SMN2CYP1A2POLB | |
| SCHEMBL12199720 | 0.76 | HRH3 (0.47) | — | |
| SCHEMBL12199712 | 0.73 | OGA (0.53) | NPC1RAB9ASMN1; SMN2CYP1A2POLB | |
| SCHEMBL12199721 | 0.73 | RAB9A (0.53) | NPC1RAB9ASMN1; SMN2CYP1A2POLB | |
| SCHEMBL31143522 | 0.73 | HRH3 (0.64) | NPC1RAB9ASMN1; SMN2CYP1A2POLB | |
| SCHEMBL12199717 | 0.73 | HRH3 (0.64) | NPC1RAB9ASMN1; SMN2CYP1A2POLB | |
| SCHEMBL26288617 | 0.70 | DRD2 (0.53) | NPC1RAB9AMEN1KMT2ADRD2 | |
| SCHEMBL12199710 | 0.70 | GRM5 (0.49) | NPC1RAB9ASMN1; SMN2OGAGRM5 | |
| SCHEMBL12199723 | 0.69 | OGA (0.50) | NPC1RAB9ASMN1; SMN2CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING PLOUGH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING PLOUGH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GID4, IL5 | SLC27A1 884/4885NPC1 608/4885RAB9A 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.